SCHEMBL5029174

SCHEMBL5029174

CC(C)S(=O)(=O)C[C@H]1C[C@H](NC(C)(C)C)CC[C@@H]1NC(=O)O

nearest known ligand 0.34

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
CCR2 P41597 7/20 0.34
SMYD3 Q9H7B4 3/20 0.32
KCNH2 Q12809 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5228128 1.00 CCR2 (0.34) CCR2SMYD3KCNH2
SCHEMBL5029171 1.00 CCR2 (0.34) CCR2SMYD3KCNH2
SCHEMBL5029532 0.90 CCR2 (0.34) CCR2SMYD3KCNH2
SCHEMBL5033541 0.79 SMYD3 (0.42) CCR2SMYD3KCNH2
SCHEMBL5033538 0.79 SMYD3 (0.42) CCR2SMYD3KCNH2
SCHEMBL5033542 0.79 SMYD3 (0.42) CCR2SMYD3KCNH2
SCHEMBL5029107 0.79 SMYD3 (0.32) SMYD3
SCHEMBL5029103 0.79 SMYD3 (0.32) SMYD3
SCHEMBL3744127 0.75 FFAR4 (0.33) CCR2
SCHEMBL3744136 0.75 FFAR4 (0.33) CCR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7378409-B2 Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB COMPANY (US) 2008-05-27 US disclosed
US-20050054626-A1 Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB COMPANY 2005-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054626-A1 Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity CCL11, CCR1, CCR2 CCR2 3/4885SMYD3 3068/4885KCNH2 1662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.